Matches in SemOpenAlex for { <https://semopenalex.org/work/W2291386925> ?p ?o ?g. }
- W2291386925 endingPage "15473" @default.
- W2291386925 startingPage "15460" @default.
- W2291386925 abstract "// Tae-Hwe Heo 1,2 , Joseph Wahler 2 and Nanjoo Suh 2,3 1 NP512, Laboratory of Pharmacoimmunology, Integrated Research Institute of Pharmaceutical Sciences, College of Pharmacy, The Catholic University of Korea, Seoul, Republic of Korea 2 Department of Chemical Biology, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, NJ, USA 3 Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA Correspondence to: Tae-Hwe Heo, email: // Nanjoo Suh, email: // Keywords : breast cancer, interleukin-6, gp130 Received : October 05, 2015 Accepted : January 23, 2016 Published : January 31, 2016 Abstract Interleukin-6 (IL-6) is a pleiotropic cytokine with known multiple functions in immune regulation, inflammation, and oncogenesis. Binding of IL-6 to the IL-6 receptor (IL-6R) induces homodimerization and recruitment of glycoprotein 130 (gp130), which leads to activation of downstream signaling. Emerging evidence suggests that high levels of IL-6 are correlated with poor prognosis in breast cancer patients. IL-6 appears to play a critical role in the growth and metastasis of breast cancer cells, renewal of breast cancer stem cells (BCSCs), and drug resistance of BCSCs, making anti–IL-6/IL-6R/gp130 therapies promising options for the treatment and prevention of breast cancers. However, preclinical and clinical studies of the applications of anti–IL-6/IL-6R/gp130 therapy in breast cancers are limited. In this review, we summarize the structures, preclinical and clinical studies, mechanisms of action of chemical and biological blockers that directly bind to IL-6, IL-6R, or gp130, and the potential clinical applications of these pharmacological agents as breast cancer therapies." @default.
- W2291386925 created "2016-06-24" @default.
- W2291386925 creator A5058977612 @default.
- W2291386925 creator A5059532915 @default.
- W2291386925 creator A5060635563 @default.
- W2291386925 date "2016-01-31" @default.
- W2291386925 modified "2023-10-01" @default.
- W2291386925 title "Potential therapeutic implications of IL-6/IL-6R/gp130-targeting agents in breast cancer" @default.
- W2291386925 cites W1514929400 @default.
- W2291386925 cites W1518308640 @default.
- W2291386925 cites W1524102446 @default.
- W2291386925 cites W1529340407 @default.
- W2291386925 cites W1538172857 @default.
- W2291386925 cites W1541406077 @default.
- W2291386925 cites W157721590 @default.
- W2291386925 cites W1583886175 @default.
- W2291386925 cites W1597588755 @default.
- W2291386925 cites W1625917256 @default.
- W2291386925 cites W1703147773 @default.
- W2291386925 cites W1836605190 @default.
- W2291386925 cites W1904767156 @default.
- W2291386925 cites W1928213272 @default.
- W2291386925 cites W19519233 @default.
- W2291386925 cites W1966859474 @default.
- W2291386925 cites W1970433764 @default.
- W2291386925 cites W1971308765 @default.
- W2291386925 cites W1975570783 @default.
- W2291386925 cites W1975801479 @default.
- W2291386925 cites W1978071867 @default.
- W2291386925 cites W1978099625 @default.
- W2291386925 cites W1978174791 @default.
- W2291386925 cites W1982319580 @default.
- W2291386925 cites W1986632581 @default.
- W2291386925 cites W1987416324 @default.
- W2291386925 cites W1988106257 @default.
- W2291386925 cites W1994464552 @default.
- W2291386925 cites W1994506340 @default.
- W2291386925 cites W1999751646 @default.
- W2291386925 cites W2006371195 @default.
- W2291386925 cites W2007606465 @default.
- W2291386925 cites W2008635725 @default.
- W2291386925 cites W2015331193 @default.
- W2291386925 cites W2022930226 @default.
- W2291386925 cites W2024171722 @default.
- W2291386925 cites W2024929694 @default.
- W2291386925 cites W2028043263 @default.
- W2291386925 cites W2028194167 @default.
- W2291386925 cites W2029227802 @default.
- W2291386925 cites W2030797581 @default.
- W2291386925 cites W2037386042 @default.
- W2291386925 cites W2042529463 @default.
- W2291386925 cites W2044702943 @default.
- W2291386925 cites W2047788682 @default.
- W2291386925 cites W2048257551 @default.
- W2291386925 cites W2054373032 @default.
- W2291386925 cites W2054480018 @default.
- W2291386925 cites W2058788010 @default.
- W2291386925 cites W2060185596 @default.
- W2291386925 cites W2066591855 @default.
- W2291386925 cites W2067219562 @default.
- W2291386925 cites W2067566784 @default.
- W2291386925 cites W2069027997 @default.
- W2291386925 cites W2074443373 @default.
- W2291386925 cites W2074601175 @default.
- W2291386925 cites W2075990748 @default.
- W2291386925 cites W2078831149 @default.
- W2291386925 cites W2086138881 @default.
- W2291386925 cites W2086629043 @default.
- W2291386925 cites W2087089570 @default.
- W2291386925 cites W2087590639 @default.
- W2291386925 cites W2087624731 @default.
- W2291386925 cites W2087768671 @default.
- W2291386925 cites W2089956125 @default.
- W2291386925 cites W2091546244 @default.
- W2291386925 cites W2092378610 @default.
- W2291386925 cites W2096960896 @default.
- W2291386925 cites W2097255042 @default.
- W2291386925 cites W2097532858 @default.
- W2291386925 cites W2097926940 @default.
- W2291386925 cites W2098776090 @default.
- W2291386925 cites W2103315206 @default.
- W2291386925 cites W2107554353 @default.
- W2291386925 cites W2108627378 @default.
- W2291386925 cites W2108725521 @default.
- W2291386925 cites W2112605252 @default.
- W2291386925 cites W2112725884 @default.
- W2291386925 cites W2114817620 @default.
- W2291386925 cites W2115585914 @default.
- W2291386925 cites W2115727543 @default.
- W2291386925 cites W2115806010 @default.
- W2291386925 cites W2118173250 @default.
- W2291386925 cites W2124618015 @default.
- W2291386925 cites W2126392005 @default.
- W2291386925 cites W2129209464 @default.
- W2291386925 cites W2132979301 @default.
- W2291386925 cites W2143196300 @default.
- W2291386925 cites W2148338934 @default.
- W2291386925 cites W2149935143 @default.